-
1 Comment
Neovasc Inc is currently in a long term downtrend where the price is trading 25.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.3.
Neovasc Inc's total revenue sank by 9.2% to $514K since the same quarter in the previous year.
Its net income has increased by 64.2% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 12.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Neovasc Inc gets an overall score of 2/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | None |
Sector | Healthcare |
Industry | Medical Devices |
Beta | 2.72 |
---|---|
Market Cap | 880K |
PE Ratio | None |
Target Price | None |
Dividend Yield | 0.0% |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for G5Z3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025